CA3244475A1 - THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC USE - Google Patents

THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC USE

Info

Publication number
CA3244475A1
CA3244475A1 CA3244475A CA3244475A CA3244475A1 CA 3244475 A1 CA3244475 A1 CA 3244475A1 CA 3244475 A CA3244475 A CA 3244475A CA 3244475 A CA3244475 A CA 3244475A CA 3244475 A1 CA3244475 A1 CA 3244475A1
Authority
CA
Canada
Prior art keywords
acetamide
isopropyl
triazin
pyrrolo
oxothieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3244475A
Other languages
English (en)
French (fr)
Inventor
Olivier Arnoud
Franck Caussanel
Rommel DADJI-FAIHUN
Gwladys LANGOT
Frank Marguet
Olivier Venier
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CA3244475A1 publication Critical patent/CA3244475A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3244475A 2022-02-21 2023-02-20 THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC USE Pending CA3244475A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22315036 2022-02-21
EP22315036.8 2022-02-21
PCT/EP2023/054138 WO2023156643A1 (en) 2022-02-21 2023-02-20 Thienopyrrolotriazine compounds, their preparation and their therapeutic use

Publications (1)

Publication Number Publication Date
CA3244475A1 true CA3244475A1 (en) 2023-08-24

Family

ID=81326677

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3244475A Pending CA3244475A1 (en) 2022-02-21 2023-02-20 THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC USE

Country Status (11)

Country Link
US (1) US20250129091A1 (cg-RX-API-DMAC7.html)
EP (1) EP4482841B1 (cg-RX-API-DMAC7.html)
JP (1) JP2025506729A (cg-RX-API-DMAC7.html)
KR (1) KR20240151767A (cg-RX-API-DMAC7.html)
CN (1) CN118843632A (cg-RX-API-DMAC7.html)
AU (1) AU2023222186A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244475A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024010803A2 (cg-RX-API-DMAC7.html)
IL (1) IL314781A (cg-RX-API-DMAC7.html)
MX (1) MX2024010216A (cg-RX-API-DMAC7.html)
WO (1) WO2023156643A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116375728B (zh) * 2021-12-31 2025-06-10 成都赜灵生物医药科技有限公司 噻吩吡咯并三嗪酮类化合物及其用途
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168012B2 (en) * 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
US20230203064A1 (en) * 2020-04-23 2023-06-29 Janssen Pharmaceutica Nv Tricyclic compounds as inhibitors of nlrp3

Also Published As

Publication number Publication date
EP4482841A1 (en) 2025-01-01
CO2024010803A2 (es) 2024-08-20
AU2023222186A1 (en) 2024-10-10
MX2024010216A (es) 2024-09-02
CN118843632A (zh) 2024-10-25
WO2023156643A1 (en) 2023-08-24
JP2025506729A (ja) 2025-03-13
KR20240151767A (ko) 2024-10-18
EP4482841B1 (en) 2026-07-15
US20250129091A1 (en) 2025-04-24
IL314781A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
AU2023263450B2 (en) Pyridazine compounds for inhibiting nlrp3
AU2022270115A1 (en) Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
AU2020421426A1 (en) RORγt inhibitor, preparation method thereof and use thereof
MXPA05001434A (es) Compuestos de dihidropirazolopiridina.
CN109071418B (zh) 氨基酸衍生物的前药
KR20250005125A (ko) NLRP3 유도체로서 유용한 피리도-[3,4-d]피리다진 아민 유도체
JP7417594B2 (ja) Trk阻害剤としてのイミダゾ[1,2-b]ピリダジン
US20250129091A1 (en) Thienopyrrolotriazine compounds, their preparation and their therapeutic use
KR20250038236A (ko) 코로나바이러스 감염 치료용 화합물
CN116583285B (zh) N-(咪唑并[1,2-b]哒嗪-3-基)-1-环己基-2H-吲唑-5-甲酰胺和N-(吡唑并[1,5-a]嘧啶-3-基)-1-环己基-2H-吲唑-5-甲酰胺衍生物作为IRAK4抑制剂用于治疗哮喘
KR20210035225A (ko) Trk 억제제로서 이미다조[1,2-b]피리다진 유도체
BR112020017121A2 (pt) Derivados de 10-(di(fenil)metil)-4-hidróxi-8,9,9a-10-tetra-hidro-7h-pirrolo[1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona e compostos relacionados como inibidores de da replicação de ortomixovírus para tratamento de influenza
CA3203129A1 (en) Imidazo[1,2-a]pyridine derivatives as irak4 inhibitors and their use in the treatment of disease
AU2023207026A1 (en) Fused heteroaryl hydroxamates as sting agonists
WO2025175247A1 (en) Imidazo-pyrazine derivatives and their use in the treatment of neurologic disorders
EA051595B1 (ru) Соединения пиридазина для ингибирования nlrp3
WO2025155786A1 (en) Bicyclic tyrosine kinase 2 inhibitors and uses thereof
CA3251045A1 (en) MODULATORS OF THE TRANSMEMBRANE CONDUCTANCE REGULATOR IN CYSTIC FIBROSIS
HK1260638B (en) Prodrug of amino acid derivative

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240816

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240820

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240820

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240820

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250130

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250130

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250130

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250211

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260128

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260128